The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein
Open Access
- 26 August 1999
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 18 (34) , 4833-4838
- https://doi.org/10.1038/sj.onc.1202848
Abstract
Mutations of the RET gene, encoding a receptor tyrosine kinase, have been associated with the inherited cancer syndromes MEN 2A and MEN 2B. They have also further been associated with both familial and sporadic medullary thyroid carcinomas. Missense mutations affecting cysteine residues within the extracellular domain of the receptor causes constitutive tyrosine kinase activation through the formation of disulfide-bonded homodimers. We have recently reported that a somatic 6 bp in-frame deletion, originally coding for Glu632-Leu633, potently activates the RET gene. This activation is increased with respect to the frequent MEN 2A-associated missense mutation Cys634Arg. This finding specifically correlated to the clinic behavior of the corresponding tumor, which was characterized by an unusually aggressive progression with both multiple and recurrent metastases. By examining the possibility that this deletion acts in a manner similar to cysteine substitution, we have analysed the molecular mechanism by which this oncogenic activation occurs. Phosphorylated dimers of the deleted Ret receptor were detected in immunoprecipitates separated under non-reducing conditions. Like other Cys point mutations, this 6 bp deletion affecting two amino acid residues between two adjacent Cys, is capable of activating the transforming ability of Ret by promoting receptor dimerization. These results suggest that alteration to cysteine residue position or pairing is capable of inducing ligand independent dimerization. Furthermore, we present data demonstrating that the processing and sorting of the Ret membrane receptor to the cell surface is affected by mutation type.Keywords
This publication has 21 references indexed in Scilit:
- Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteinesOncogene, 1998
- Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogeneOncogene, 1997
- The Full Oncogenic Activity of Ret/ptc2 Depends on Tyrosine 539, a Docking Site for Phospholipase CγMolecular and Cellular Biology, 1996
- Mechanism of Activation of the ret Proto-oncogene by Multiple Endocrine Neoplasia 2A MutationsMolecular and Cellular Biology, 1995
- Mutation of the RET protooncogene in sporadic medullary thyroid carcinomaGenes, Chromosomes and Cancer, 1995
- RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancerHuman Molecular Genetics, 1994
- Single missense mutation in the tyrosine kinasecatalytic domain of the RET protooncogene is associated with multiple endocrineneoplasia type 2B.Proceedings of the National Academy of Sciences, 1994
- Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumoursHuman Molecular Genetics, 1994
- Mutations in the RET proto-oncogene are associated with MEN 2A and FMTCHuman Molecular Genetics, 1993
- Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.Molecular and Cellular Biology, 1993